TY - JOUR
TI - Medullary thyroid carcinoma (MTC): Unusual metastatic sites
AU - Kazakou, P.
AU - Simeakis, G.
AU - Alevizaki, M.
AU - Saltiki, K.
JO - Endocrinology, Diabetes and Metabolism Case Reports
PY - 2021
VL - 2021
TODO - 1
SP - null
PB - BioScientifica Ltd
SN - null
TODO - 10.1530/EDM-21-0063
TODO - calcitonin;  carcinoembryonic antigen;  chromogranin A;  homeobox protein Nkx 2.1;  synaptophysin;  vandetanib, aged;  Article;  bone metastasis;  cancer growth;  cancer radiotherapy;  cancer staging;  case report;  chemoembolization;  clinical article;  computer assisted tomography;  distant metastasis;  echography;  female;  fine needle aspiration biopsy;  human;  immunohistochemistry;  liver metastasis;  lymph node dissection;  lymph node metastasis;  mammography;  mandible tumor;  mediastinum metastasis;  metastatic breast cancer;  middle aged;  nuclear magnetic resonance imaging;  pancreas metastasis;  response evaluation criteria in solid tumors;  thyroid medullary carcinoma;  tumor volume
TODO - Medullary thyroid carcinoma (MTC) has a varying clinical course; distant metastases are frequently present even at diagnosis. We present two MTC cases with unusual metastatic sites. Two female patients are presented with slow progressive MTC. The first case developed distant metastases 23 years after diagnosis and underwent locoregional therapies. At the same time a breast mass developed representing MTC metastasis. Treatment with vandetanib led to long-term disease stabilization. The second patient is presented with metastases in the pancreas 13 years after diagnosis. Shortly, a painful mass developed in the mandible and metastasis of MTC was diagnosed. Disease progression was recorded 20 months after the initiation of local and systemic therapy. Such cases have only rarely been reported in the literature and highlight the need for prompt recognition of unexpected MTC metastases. © 2021 The authors.
ER -